Related Experiment Video
Updated: Jun 10, 2026
Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining
Published on: May 23, 2025
Methylphenidate improves cognitive deficits produced by infantile iron deficiency in rats
Wael M Y Mohamed1, Erica L Unger, Sarita K Kambhampati
1Neuroscience Institute, Penn State University, USA.
Insights
Early life iron deficiency causes lasting cognitive impairment in rats, similar to humans. Methylphenidate (MePh) treatment improved cognitive deficits in iron-deficient rats, suggesting a potential pharmacological therapy.
Area of Science:
- Neuroscience
- Developmental Biology
- Nutritional Science
Background:
- Early-life iron deficiency in humans leads to persistent cognitive deficits.
- Current dietary iron replacement strategies do not fully correct these impairments.
- Pharmacological treatments for early iron deficiency-induced cognitive deficits remain unexplored.
Purpose of the Study:
- To determine if early-life iron deficiency in rats replicates human adolescent cognitive deficits.
- To investigate the potential of methylphenidate (MePh) as a pharmacological treatment for these deficits.
Main Methods:
- Sprague-Dawley rats were made iron deficient (ID) from postnatal day 4.
- Cognitive function was assessed using attention set-shift tasks at 45 days of age.
- Following initial testing, animals received daily methylphenidate (MePh) or vehicle for 15 days before re-testing.
Main Results:
- Iron-deficient (ID) rats exhibited poorer performance on attention set-shift tasks compared to controls.
- Methylphenidate (MePh) administration significantly improved cognitive performance in ID rats.
- Lower doses of MePh were more effective than higher doses in ameliorating the deficits.
Conclusions:
- Early-life iron deficiency induces persistent cognitive deficits in rats, mirroring human conditions.
- Methylphenidate (MePh) shows promise as a pharmacological intervention for cognitive impairments resulting from early iron deficiency.
- These findings suggest a potential therapeutic avenue for treating children with severe early-life iron deficiency-related cognitive issues.
Abstract:
In humans, iron deficiency early in life produces persistent, impaired cognition. Dietary iron replacement does not ameliorate these problems and to date, no attempt to treat these individuals pharmacologically has been reported. The aim of this work was to test the hypothesis that rats made iron deficient in early infancy exhibit cognitive deficits similar to those seen in humans at adolescence. A second aim was to investigate whether the deficit could be treated pharmacologically. Sprague-Dawley rats were made iron deficient (ID) starting at postnatal day 4 by being placed with iron-deficient dams (vs. control). At weaning, all pups were placed on an iron-sufficient diet for the remainder of the study. At 45 days of age, the animals were tested for attention set shifting. After testing, the animals were assigned to one of three methylphenidate (MePh) dose groups, 1, 5 or 10 mg/kg, p.o., vs. vehicle control and treated daily for 15 days prior to a second round of attention set shift testing and continued throughout testing. The results showed that ID rats performed more poorly than controls overall on attentional set-shift testing. MePh improved ID rats' performance and lower doses were more effective than higher doses. This is the first demonstration that MePh can improve cognitive deficits produced by early ID in animals. These findings may open the possibility of pharmacotherapy to treat the persistent cognitive difficulties in children who were severely iron deficient in early infancy.
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists